Mark Mallon joined Ironwood in January 2019 following a distinguished 24-year career at AstraZeneca where he held a variety of senior executive positions. He most recently served as a member of its executive committee as executive vice president of global product and portfolio strategy leading global marketing, commercial operations, pricing and market access, medical affairs and corporate affairs. Prior to his most recent role, he launched AstraZeneca’s emerging market strategy and led its multibillion dollar international business, including in China where AstraZeneca was the second largest and fastest growing multinational pharmaceutical company. In his leadership roles at AstraZeneca, including president of AstraZeneca China, chief operating officer of AstraZeneca Japan, vice president of U.S. sales and marketing operations and president of AstraZeneca Italy, Mark delivered several best-in-class new product launches. He is also widely respected for building leading GI franchises, earned from his time leading the U.S. commercial and drug development programs for all AstraZeneca GI products. During his tenure running U.S. GI therapeutics for AstraZeneca, sales of Prilosec® (omeprazole) – already the largest selling pharmaceutical in the world – grew 35% and the company successfully launched Nexium® (esomeprazole), Entocort® EC (budesonide) and Prilosec OTC® (with partner The Procter & Gamble Company). Mark has a B.S. in chemical engineering from the University of Pennsylvania and an MBA in marketing and finance from the Wharton School of Business.